Generic Drug Policies in Latin America

Vista sencilla de ítem
dc.creatorHomedes, Núria
dc.creatorLópez Linares, Roberto
dc.creatorUgalde, Antonio
dc.date2013-05-29T17:51:59Z
dc.date2013-05-29T17:51:59Z
dc.date2005-03
dc.date.accessioned2026-07-01T01:25:33Z
dc.descriptionThe World Health Organization and pharmaceutical experts have recommended that Generic Drug Policies be implemented to improve the availability of affordable medicines. This document reports on the status of generic drug policies in Latin America. The data presented are based on several sources: a survey conducted in 2003, archival information, and official health and pharmaceutical policy documents. The survey revealed that countries use different definitions for the terms generic and bioequivalence severely curtailing the ability to make comparisons across countries. There is also ample variability in the periods allowed for drug registration and registration charges. Although most countries in the region are becoming increasingly dependent on pharmaceutical imports, many have sizeable local pharmaceutical manufacturing capacity. The need to adopt common definitions for technical terms, the urgency of improving quality controls and the importance of strengthening generic drug programs are highlighted.
dc.formatapplication/pdf
dc.formattext/plain
dc.identifierhttp://documents.worldbank.org/curated/en/2005/03/5734957/generic-drug-policies-latin-america
dc.identifierhttps://hdl.handle.net/10986/13639
dc.identifierhttps://doi.org/10.1596/13639
dc.identifier.urihttp://hdl.handle.net/123456789/417976
dc.languageEnglish
dc.languageen_US
dc.publisherWorld Bank, Washington, DC
dc.relationHealth, Nutrition and Population (HNP) discussion paper;
dc.rightsCC BY 3.0 IGO
dc.rightshttp://creativecommons.org/licenses/by/3.0/igo/
dc.rightsWorld Bank
dc.subjectACCESS TO PHARMACEUTICALS
dc.subjectACTIVE INGREDIENTS
dc.subjectBIOEQUIVALENCE
dc.subjectBRAND NAME
dc.subjectBRAND NAME DRUGS
dc.subjectBRAND NAMES
dc.subjectBRANDED GENERIC DRUGS
dc.subjectCLINICAL TRIALS
dc.subjectCOMMERCIALIZATION
dc.subjectCOUNTERFEIT DRUGS
dc.subjectDRUG MANUFACTURING
dc.subjectDRUG POLICIES
dc.subjectDRUG POLICY
dc.subjectDRUG PRICES
dc.subjectESSENTIAL DRUGS
dc.subjectGENERIC DRUGS
dc.subjectGENERIC PRODUCTS
dc.subjectGENERIC SUBSTITUTION
dc.subjectGMP
dc.subjectGOOD MANUFACTURING PRACTICES
dc.subjectHEALTH CARE
dc.subjectHEALTH POLICY
dc.subjectHEALTH SERVICES
dc.subjectHOSPITALS
dc.subjectHUMAN DEVELOPMENT
dc.subjectLABORATORIES
dc.subjectLATIN AMERICAN
dc.subjectLAWS
dc.subjectLOCAL PRODUCTION
dc.subjectMARKET VALUE
dc.subjectMEDICINE
dc.subjectMEDICINES
dc.subjectNATIONAL DRUG POLICIES
dc.subjectNEW PRODUCT DEVELOPMENT
dc.subjectNUTRITION
dc.subjectPATIENTS
dc.subjectPHARMACEUTICAL INDUSTRY
dc.subjectPHARMACEUTICAL MANUFACTURING
dc.subjectPHARMACEUTICAL POLICIES
dc.subjectPHARMACEUTICAL POLICY
dc.subjectPHARMACEUTICAL PRODUCTION
dc.subjectPHARMACEUTICAL PRODUCTS
dc.subjectPHARMACEUTICAL REGISTRATION
dc.subjectPHARMACEUTICALS
dc.subjectPHARMACISTS
dc.subjectPHARMACOLOGY
dc.subjectPHARMACY
dc.subjectPHYSICIANS
dc.subjectPOLICY DOCUMENTS
dc.subjectPRESCRIPTIONS
dc.subjectPRICE CONTROLS
dc.subjectPRIVATE SECTOR
dc.subjectPROCUREMENT
dc.subjectPUBLIC HEALTH
dc.subjectPUBLIC SECTOR
dc.subjectQUALITY
dc.subjectQUALITY ASSURANCE
dc.subjectRETAIL
dc.subjectSAFETY
dc.subjectSALES
dc.subjectSTRATEGIC PLANNING
dc.subjectSUPPLIERS
dc.titleGeneric Drug Policies in Latin America

Archivos

Colecciones

AgroKnow